{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003671","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.014406+00:00","generated_at":"2026-06-04T09:55:08.477386+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NextCure reports FY2023 net loss $62.7M; workforce cut 37% to extend cash runway to H2 2026","bullets":["Cash, equivalents, and marketable securities $108.3M at Dec 31, 2023 (down from $159.9M); net loss $62.7M vs $74.7M prior year.","Workforce reduction ~37%; internal GMP manufacturing paused; one-time restructuring charges ~$0.8M expected in Q2 2024.","NC410 combo: 42.8% ORR (3 PRs in 7 evaluable ovarian patients); CRC cohort 10.5% ORR (2/19), median PFS 8.1 months.","LNCB74 (B7-H4 ADC) IND planned by year-end 2024; cost-sharing with LegoChem Biosciences.","Cash runway now expected into second half of 2026 following restructuring and cost reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003671","json":"https://secwatch.observer/filing/0001558370-24-003671.json","markdown":"https://secwatch.observer/filing/0001558370-24-003671.md","text":"https://secwatch.observer/filing/0001558370-24-003671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024003671/0001558370-24-003671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024003671/nxtc-20240321x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:55:08.477386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60ce761c371a5a9bf88667e52583ecd91cf0cf73","claim":"NextCure, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024003671/0001558370-24-003671-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}